The stock value of Delcath Systems, Inc. (NASDAQ: DCTH) has significantly increased as a consequence of the publication of encouraging findings from an independent investigation. DCTH shares have increased by 10.42% as of the latest current-market check, hitting $10.07 on US stock charts.
Delcath announced Release of a notable independent study
Delcath Systems announced today that a noteworthy retrospective research has been published in the *Annals of Surgical Oncology*. Researchers from Tampa, Florida’s Moffitt Cancer Center conducted a study to look at the efficacy of treating hepatic metastases from uveal melanoma using Delcath’s HEPZATO KIT, which contains melphalan and the Hepatic Delivery System (HDS).
The study was tilted “Hepatic and Overall Progression-Free Survival After Percutaneous Hepatic Perfusion (PHP) as First-Line or Second-Line Therapy for Metastatic Uveal Melanoma.”
Key DCTH Study Findings
Compared to immunotherapy and other liver-directed therapies, the HEPZATO KIT improves progression-free survival and provides greater disease control in the liver, according to a trial including thirty patients. In particular, patients who received HEPZATO KIT as a second-line treatment had an OS of 18.4 months, compared to 22.4 months for those treated with it as a first-line therapy.
When used as a first-line treatment, the HEPZATO KIT achieved a median Hepatic Progression-Free Survival (hPFS) of 17.6 months, surpassing the 8.8 months observed with immunotherapy and the 9.2 months seen with other liver-directed therapies. In the second-line therapy setting, the median hPFS with HEPZATO KIT was not reached, indicating superior outcomes compared to the alternatives.
Implications and Future Directions
First-line HEPZATO KIT therapy had a median overall Progression-Free Survival (PFS) of 15.4 months; immunotherapy had an 8.8-month PFS and other liver-directed therapies had a 9.2-month PFS. The HEPZATO KIT produced a median PFS of 22.2 months for second-line treatment, which was higher than the median PFS of 14.7 months and 7.5 months for immunotherapy and other liver-directed alternatives.
These results underscore the efficacy of melphalan/HDS in managing liver-dominant metastatic uveal melanoma. Delcath Systems plans to further investigate the integration of melphalan/HDS with systemic therapies to enhance patient outcomes and continue advancing treatment options.
